Across TCGA pan-cancer cohorts, LSM10 mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated LSM10 data layer compared with 26 for mass-spec protein and 3 for mutation status.
The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher LSM10 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated LSM10 expression acts as an unfavorable survival marker.
LSCC are the cancer types where LSM10 mass-spec protein most reproducibly stratifies survival.